FLGT Fulgent Genetics, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1674930 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.7%
TTM net income YoY-111.5%
TTM EPS YoY-135.1%
Revenue 3-yr CAGR4.9%
Net income 3-yr CAGR—
Margins
Gross margin33.8%
Operating margin-39.2%
Net margin-27.5%
FCF margin-0.4%
EBITDA margin-32.8%
Returns
ROE-8.6%
ROA-7.9%
ROIC (approx.)-10.7%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio5.34x
Interest coverage-1,307.88x
Cash quality & payout
Operating cash flow / net income-0.16x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue4.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $90.41M | $85.39M | $71.14M | $83.34M | $84.07M | $81.80M | $73.46M | $76.21M |
| Cost of revenue | $58.47M | $59.71M | $49.65M | $50.75M | $48.56M | $47.37M | $45.12M | $44.37M |
| Gross profit | $31.95M | $25.68M | $21.49M | $32.58M | $35.51M | $34.44M | $28.35M | $31.85M |
| R&D expense | $13.64M | $14.55M | $14.18M | $14.17M | $13.86M | $13.48M | $12.39M | $12.11M |
| SG&A expense | $22.76M | $27.20M | $27.68M | $41.65M | $23.34M | $26.39M | $25.29M | $24.34M |
| Operating income | -$22.55M | -$36.07M | -$34.62M | -$36.24M | -$15.35M | -$19.71M | -$19.80M | -$16.14M |
| Interest expense | $7,000 | $59,000 | $17,000 | $16,000 | $28,000 | $17,000 | $14,000 | $40,000 |
| Pretax income | -$14.04M | -$29.69M | -$25.98M | -$29.27M | -$7.51M | -$21.52M | -$11.72M | -$8.04M |
| Income tax | -$704,000 | $29,000 | -$704,000 | -$5.62M | -$683,000 | -$2.26M | $176,000 | -$1.85M |
| Net income | -$13.15M | -$29.53M | -$24.83M | -$23.42M | -$6.61M | -$18.96M | -$11.53M | -$5.89M |
| EBITDA | -$18.35M | -$31.07M | -$28.62M | -$30.13M | -$11.45M | -$15.81M | -$13.88M | -$9.94M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | 27.66M | 28.00M | 30.88M | — | 30.75M | 30.54M | 30.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $86.79M | $26.30M | $23.40M | $50.19M | $117.64M | $87.88M | $67.28M | $55.28M |
| Short-term investments | $205.95M | $230.73M | $252.90M | $285.88M | — | — | — | $202.96M |
| Receivables | $62.49M | $64.94M | $69.28M | $84.76M | $71.19M | $77.19M | $71.48M | $69.02M |
| Inventory | $661,000 | $793,000 | $770,000 | — | — | — | — | — |
| Current assets | $383.74M | $454.77M | $479.04M | $550.49M | $507.37M | $428.73M | $416.78M | $353.57M |
| PP&E, net | $110.74M | $113.07M | $116.34M | $112.55M | $111.86M | $110.22M | $107.08M | $105.55M |
| Goodwill | $53.86M | $53.86M | $53.73M | $25.08M | $25.08M | $22.05M | $22.05M | $22.05M |
| Intangibles | $146.80M | $149.26M | $153.99M | $133.28M | $135.25M | $135.25M | $133.01M | $134.98M |
| Total assets | $1.08B | $1.09B | $1.16B | $1.21B | $1.21B | $1.20B | $1.21B | $1.22B |
| Current liabilities | $71.88M | $71.76M | $90.13M | $84.97M | $72.43M | $71.33M | $65.92M | $72.90M |
| Total liabilities | $94.22M | $93.24M | $112.22M | $106.81M | $93.81M | $88.20M | $82.97M | $90.81M |
| Shareholders' equity | $990.49M | $1.00B | $1.05B | $1.11B | $1.13B | $1.12B | $1.13B | $1.13B |
| Shares outstanding | 27.76M | 27.52M | 28.85M | 31.08M | 30.85M | 30.61M | 30.62M | 30.84M |
| Cash flow statement | ||||||||
| Operating cash flow | $109.23M | -$23.76M | $7.10M | -$78.14M | $11.11M | -$30.17M | -$4.43M | $25.02M |
| Capital expenditure | $1.79M | $3.86M | $5.20M | $4.98M | $6.05M | $6.83M | $4.72M | $3.78M |
| Free cash flow | $107.44M | -$27.62M | $1.90M | -$83.12M | $5.06M | -$37.00M | -$9.15M | $21.24M |
| Investing cash flow | -$48.04M | $50.80M | $10.94M | $11.15M | $19.08M | $53.40M | $27.73M | -$27.45M |
| Financing cash flow | -$724,000 | -$24.23M | -$44.83M | -$534,000 | -$445,000 | -$2.64M | -$11.17M | -$327,000 |
| Depreciation & amortization | $4.20M | $5.00M | $6.00M | $6.11M | $3.90M | $3.90M | $5.92M | $6.19M |
| Stock-based compensation | $8.12M | $8.62M | $9.89M | $9.28M | $9.72M | $10.04M | $10.55M | $10.41M |
| Share buybacks | $251,000 | $23.80M | $40.08M | $0 | $0 | $2.21M | $8.68M | $0 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.